Yan Ji1, Rachel Isaksson Vogel1, Emil Lou1. 1. Division of Hematology, Oncology and Transplantation , University of Minnesota , Minneapolis, MN (Y.J., E.L.); Masonic Cancer Center, Biostatistics and Bioinformatics , University of Minnesota , Minneapolis, MN (R.I.V.).
Abstract
BACKGROUND: Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare variants of pituitary tumors for which no evidence-based treatment currently exists. We sought to determine whether temozolomide represents an effective chemotherapeutic option for patients with PC and APA. METHODS: A systematic review was performed using all published cases of PC and APA treated with temozolomide, and for which information on treatment regimen, clinical response, and survival could be identified. The primary goal of this analysis was to describe overall survival and progression-free survival among PC and APA patients after temozolomide treatment. Secondary goals included assessment of response rate and biomarkers of response. RESULTS: We identified 57 cases and obtained follow-up data on 54 patients (31 APA and 23 PC) for analysis. Estimates of 5-year progression-free survival and overall survival were 21.9% and 57.4% for patients with APA and 36.1% and 56.2% for patients with PC. Among those who responded to temozolomide, overall survival was marginally statistically significantly greater for patients on long-term temozolomide therapy compared with those who were not (5-year overall survival 91.7% vs 54.1%, P = .08); Progression-free survival results were similar but not statistically significant. The objective response rate was 48.4% for patients with APA and 65.2% for patients with PC. Stable disease occurred in 29% of APA and 17.4% of PC patients. Neither histology nor expression of Ki-67 correlated with response; however, negative O6-methylguanine-DNA methyltransferase staining was strongly related to response to temozolomide in patients with APA (P < .001). CONCLUSIONS: Temozolomide is an effective treatment of both PC and APA, and long-term treatment can be considered for particularly aggressive cases.
BACKGROUND:Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare variants of pituitary tumors for which no evidence-based treatment currently exists. We sought to determine whether temozolomide represents an effective chemotherapeutic option for patients with PC and APA. METHODS: A systematic review was performed using all published cases of PC and APA treated with temozolomide, and for which information on treatment regimen, clinical response, and survival could be identified. The primary goal of this analysis was to describe overall survival and progression-free survival among PC and APA patients after temozolomide treatment. Secondary goals included assessment of response rate and biomarkers of response. RESULTS: We identified 57 cases and obtained follow-up data on 54 patients (31 APA and 23 PC) for analysis. Estimates of 5-year progression-free survival and overall survival were 21.9% and 57.4% for patients with APA and 36.1% and 56.2% for patients with PC. Among those who responded to temozolomide, overall survival was marginally statistically significantly greater for patients on long-term temozolomide therapy compared with those who were not (5-year overall survival 91.7% vs 54.1%, P = .08); Progression-free survival results were similar but not statistically significant. The objective response rate was 48.4% for patients with APA and 65.2% for patients with PC. Stable disease occurred in 29% of APA and 17.4% of PC patients. Neither histology nor expression of Ki-67 correlated with response; however, negative O6-methylguanine-DNA methyltransferase staining was strongly related to response to temozolomide in patients with APA (P < .001). CONCLUSIONS:Temozolomide is an effective treatment of both PC and APA, and long-term treatment can be considered for particularly aggressive cases.
Authors: Marco Losa; Elena Mazza; Maria Rosa Terreni; Ann McCormack; Anthony J Gill; Micaela Motta; Maria Giulia Cangi; Anna Talarico; Pietro Mortini; Michele Reni Journal: Eur J Endocrinol Date: 2010-09-24 Impact factor: 6.664
Authors: Camilo E Fadul; Andrew L Kominsky; Louise P Meyer; Linda S Kingman; William B Kinlaw; C Harker Rhodes; Clifford J Eskey; Nathan E Simmons Journal: J Neurosurg Date: 2006-10 Impact factor: 5.115
Authors: H Bode; M Seiz; A Lammert; M A Brockmann; W Back; H-P Hammes; C Thomé Journal: Exp Clin Endocrinol Diabetes Date: 2010-05-21 Impact factor: 2.949
Authors: Zachary M Bush; Janina A Longtine; Tracy Cunningham; David Schiff; John A Jane; Mary Lee Vance; Michael O Thorner; Edward R Laws; M Beatriz S Lopes Journal: J Clin Endocrinol Metab Date: 2010-07-28 Impact factor: 5.958
Authors: Jana Phillips; Honey E East; Sarah E French; Eugen Melcescu; Robert D Hamilton; William C Nicholas; Jonathan F Fratkin; Andrew D Parent; Gustavo Luzardo; Christian A Koch Journal: Hormones (Athens) Date: 2012 Oct-Dec Impact factor: 2.885
Authors: Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn Journal: Eur J Endocrinol Date: 2007-02 Impact factor: 6.664
Authors: B C Whitelaw; D Dworakowska; N W Thomas; S Barazi; P Riordan-Eva; A P King; T Hampton; D B Landau; D Lipscomb; C R Buchanan; J A Gilbert; S J B Aylwin Journal: Clin Endocrinol (Oxf) Date: 2012-06 Impact factor: 3.478
Authors: Ashley L B Raghu; Megan C Everson; Ahmed Helal; Satoshi Kiyofuji; Michelle J Clarke; Michael J Link Journal: J Neurol Surg B Skull Base Date: 2021-03-01
Authors: Maria Chiara Decaroli; Anna Ansaloni; Maria Laura Monzani; Marco Losa; Elena Zunarelli; Vincenzo Rochira; Bruno Madeo Journal: J Endocr Soc Date: 2021-04-10
Authors: Justin T Jordan; Julie J Miller; Tucker Cushing; Marlon Seijo; Tracy T Batchelor; Isabel C Arrillaga-Romany; Helen A Shih; Lisa B Nachtigall; Jay S Loeffler; Jorg Dietrich Journal: Neurooncol Pract Date: 2017-05-26